195 related articles for article (PubMed ID: 26398503)
1. Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.
Lepida A; Colombo M; Fernandez I; Abdurakhmanov D; Ferreira PA; Strasser SI; Urbanek P; Mangia A; Calleja JL; Iraqi W; DeMasi R; Lonjon-Domanec I; Moreno C; Wedemeyer H
PLoS One; 2015; 10(9):e0138503. PubMed ID: 26398503
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
[TBL] [Abstract][Full Text] [Related]
3. Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
Colombo M; Strasser S; Moreno C; Abrao Ferreira P; Urbanek P; Fernández I; Abdurakmonov D; Streinu-Cercel A; Verheyen A; Iraqi W; DeMasi R; Hill A; Lonjon-Domanec I; Wedemeyer H
J Hepatol; 2014 Nov; 61(5):976-83. PubMed ID: 24946280
[TBL] [Abstract][Full Text] [Related]
4. Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme.
Gori A; Doroana M; Chernova O; Rockstroh JK; Banhegyi D; Bergin C; Verucchi G; Liu C; DeMasi R; Hadacek B; Nelson M
J Infect; 2015 Dec; 71(6):675-82. PubMed ID: 26416471
[TBL] [Abstract][Full Text] [Related]
5. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy.
Sáez-Royuela F; Linares P; Cervera LA; Almohalla C; Jorquera F; Lorenzo S; García I; Karpman G; Badia E; Vallecillo MA; Moncada A; Calvo S; Olcoz JL;
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):305-12. PubMed ID: 26636405
[TBL] [Abstract][Full Text] [Related]
7. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
Coilly A; Dumortier J; Botta-Fridlund D; Latournerie M; Leroy V; Pageaux GP; Agostini H; Giostra E; Moreno C; Roche B; Antonini TM; Guillaud O; Lebray P; Radenne S; Saouli AC; Calmus Y; Alric L; Debette-Gratien M; De Ledinghen V; Durand F; Duvoux C; Samuel D; Duclos-Vallée JC
PLoS One; 2015; 10(9):e0138091. PubMed ID: 26394142
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.
D'Ambrosio R; Aghemo A; Fraquelli M; Rumi MG; Donato MF; Paradis V; Bedossa P; Colombo M
J Hepatol; 2013 Aug; 59(2):251-6. PubMed ID: 23528378
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.
Stasi C; Piluso A; Arena U; Salomoni E; Montalto P; Monti M; Boldrini B; Corti G; Marra F; Laffi G; Milani S; Zignego AL
World J Gastroenterol; 2015 Mar; 21(10):3013-9. PubMed ID: 25780300
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
Salmerón J; Vinaixa C; Berenguer R; Pascasio JM; Sánchez Ruano JJ; Serra MÁ; Gila A; Diago M; Romero-Gómez M; Navarro JM; Testillano M; Fernández C; Espinosa D; Carmona I; Pons JA; Jorquera F; Rodriguez FJ; Pérez R; Montero JL; Granados R; Fernández M; Martín AB; Muñoz de Rueda P; Quiles R;
World J Gastroenterol; 2015 Aug; 21(30):9163-74. PubMed ID: 26290644
[TBL] [Abstract][Full Text] [Related]
12. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.
Kwo PY; Ghabril M; Lacerda MA; Joseph Tector A; Fridell JA; Vianna R
Clin Transplant; 2014 Jun; 28(6):722-7. PubMed ID: 24708229
[TBL] [Abstract][Full Text] [Related]
13. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
Bruno S; Vierling JM; Esteban R; Nyberg LM; Tanno H; Goodman Z; Poordad F; Bacon B; Gottesdiener K; Pedicone LD; Albrecht JK; Brass CA; Thompson S; Burroughs MH
J Hepatol; 2013 Mar; 58(3):479-87. PubMed ID: 23183529
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
16. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
Macías J; Rivero A
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():33-6. PubMed ID: 24063901
[TBL] [Abstract][Full Text] [Related]
17. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
Maida I; Martin-Carbonero L; Sotgiu G; Vispo E; Barreiro P; Gonzalez-Lahoz J; Soriano V
J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891
[TBL] [Abstract][Full Text] [Related]
18. Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy.
Morisco F; Masarone M; Rosato V; Camera S; Granata R; Tartaglione MT; Coppola C; Coppola N; Salomone-Megna A; Gentile I; De Luna A; Federico A; Precone D; Claar E; Abenavoli L; Persico M
Rev Recent Clin Trials; 2016; 11(4):306-316. PubMed ID: 26672601
[TBL] [Abstract][Full Text] [Related]
19. Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.
Crismale JF; Martel-Laferrière V; Bichoupan K; Schonfeld E; Pappas A; Wyatt C; Odin JA; Liu LU; Schiano TD; Perumalswami PV; Bansal M; Dieterich DT; Branch AD
Liver Int; 2014 Aug; 34(7):1018-24. PubMed ID: 24118693
[TBL] [Abstract][Full Text] [Related]
20. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]